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Abstract
The purpose of the study was to investigate the clinical factors influencing the prognosis of patients submitted to hepa-
tectomy for metastases from gastric cancer and their clinical role. We conducted a retrospective multicentre review. We 
evaluated how survival from surgery was influenced by patient-related, tumour-related and treatment-related prognostic 
factors. We analysed data on 144 patients submitted to hepatectomy for metastases from gastric cancer, in the synchronous 
and metachronous setting. In 117 cases, an R0 resection was achieved, while in 27 an R + hepatic resection was performed. 
Chemotherapy was administered to 55 patients. Surgical mortality was 2.1% and morbidity 21.5%. One-, 3-, and 5-year OS 
rates after surgery were 49.9, 19.4 and 11.6%, respectively, with a median OS of 12.0 months. T4 gastric cancer, H3 hepatic 
involvement, non-curative resection, recurrence after surgery, and abstention from chemotherapy were associated with a 
worse prognosis. Factor T and H displayed a clear (p < 0.001) cumulative effect. Our data show that R0 resection must be 
pursued whenever possible. The treatment of T4 gastric cancer with hepatic bilateral and diffuse metastasis (H3) should be 
considered carefully or it should be probably avoided. Finally, a multimodal treatment associating surgery and chemotherapy 
offers the best survival results.
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Introduction
In recent years, surgical treatment of hepatic metastases 
from gastric cancer has been widely discussed in an effort to 
ameliorate the oncologic results offered by palliative chemo-
therapy or supportive care [1–18].
We contributed to the debate through previous publica-
tions, showing that simple clinical elements may help in 
the selection of good candidates for surgery, both in the 
metachronous [19] and in the synchronous [20] setting, and 
that the possibility to achieve a curative resection is the main 
prognostic element in this group of patients. Moreover, we 
found that administration of chemotherapy positively influ-
enced the overall survival of metastatic patients treated with 
surgery.
In this invited paper, included in an almost monographic 
issue addressing gastric cancer through different hot top-
ics, we want to present the most recent data concerning 
the surgical treatment of hepatic metastases from gastric 
cancer obtained from the analysis of the experience of the 
major Institutions participating in the Italian Gastric Cancer 
Research Group.
Methods
We retrospectively reviewed the data of 144 gastric cancer 
patients submitted to surgical treatment for both synchronous 
and metachronous hepatic metastases from 1990 to Janu-
ary 2017. The data were extrapolated from a prospectively 
collected multicentric database, shared by six institutions, 
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members of the Italian Research Group on Gastric Cancer. 
Data were managed according to institutional rules with 
patient consent.
Preoperative workup systematically included computed 
tomography, while hepatic MRI and staging laparoscopy 
were not routinely employed, particularly for patients treated 
before 2010. Patients with preoperative evidence of direct 
infiltration of the hepatic parenchyma from the gastric pri-
mary were not considered as well as those with extrahepatic 
metastases identified before surgery.
Pathologic data concerning the gastric primary were col-
lected as suggested by the General Rules of the IGCA and 
classified following the 7th AICC-TNM system. The extent 
of hepatic involvement was classified according to the JGCA 
H grading of liver involvement [21].
Follow-up was structured as already described [22] and 
stopped on 1 June 2017. We evaluated how survival from 
diagnosis was influenced by patients-, gastric cancer-, metas-
tasis-, and treatment-related prognostic factors, as detailed 
in Table 1.
Statistical analysis
Descriptive statistics are presented as median and inter-
quartile range (IQR 25–75%) or confidence interval (CI). 
Comparisons between groups were obtained through Chi 
square analysis for discrete variables and through t Student’s 
test analysis for continuous variables. Overall survival (OS) 
was measured from the date of resection to the date of death 
or the latest follow-up. Survival curves were generated by 
the Kaplan–Meier method, and statistical significance was 
determined using the log-rank test. Only variables that were 
statistically significant (p < 0.05) at univariate analysis were 
considered for multivariate analysis with Cox proportional 
hazards model.
Results
In this study, we considered 144 patients, 94 males and 50 
females. Median age was 68 years (IQR 59.5–75 years). 
One-hundred and twelve patients (77.8%) presented syn-
chronous hepatic metastases at the diagnosis of gastric 
cancer, while 32 (22.2%) developed metachronous hepatic 
metastases after curative gastrectomy.
Gastric cancer was treated in all patients with radical 
surgery, associated in 75.7% of cases to D2 lymphadenec-
tomy; D1 lymphadenectomy was performed in 11 patients 
(7.6%), as well as D3 lymphadenectomy. Hepatic resec-
tion was achieved by single or multiple metastasectomy in 
108 cases (75.0%), segmentectomy/bisegmentectomy in 24 
cases (16.7%), and major hepatic resection in 12 (8.3%). 
In the synchronous setting, 13 patients (11.6%) also had 
other extrahepatic metastases, detected at laparotomy: in 
6 cases limited peritoneal metastases and in 7 cases dis-
tant intraabdominal lymphonodal metastases. In five cases, 
these extrahepatic metastases were resected.
































Timing of hepatic metastases
 Synchronous 112 77.8
 Metachronous 32 22.2







Location of extrahepatic metastases
 Peritoneal 7 4.9
 Lymphonodal 6 4.2
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A radical resection (R0) was obtained in 117 cases 
(81.2%), while a microscopically (R1) or macroscopically 
(R2) non-curative resection was obtained in 14 (9.7%) and 
13 cases (9.1%), respectively. The most common reasons 
for non-curative resection were unexpected intraoperative 
upstaging of the factor H, the critical position of hepatic 
lesion/s, and the presence of other extrahepatic metastasis.
Postoperative complication rate was 21.5% and three 
patients (2.1%) died during the postoperative period 
(Table 2).
In the synchronous setting, preoperative chemotherapy 
was administered in 16 cases (14.3%); 28 patients (25.0%) 
received postoperative chemotherapy, while 4 patients 
(3.6%) received both pre- and postoperative chemotherapy. 
Among patients treated with postoperative chemotherapy 
(alone or associated with preoperative treatment), seven 
(21.2%) had not received a curative resection. With regard 
to patients with metachronous hepatic metastases, chemo-
therapy was administered only in seven cases (22.6%).
Twenty-six patients (18%) were alive at the time we 
stopped follow-up; 22 of them had no tumour relapse, while 
4 had haematogenous recurrence. Five patients died due to 
other causes than tumour recurrence and six patients were 
lost at follow-up. One-hundred and eleven patients (77.1%) 
died because of gastric cancer recurrence. This was haema-
togenous in 42 cases, peritoneal in 5, and in the regional 
nodes in 4; the details of recurrence were unknown in 60 
cases.
One-, 3-, and 5-year OS rates after surgery were 49.9, 
19.4, and 11.6%, respectively (Fig. 1), with a median OS of 
12.0 months (CI 95% 8.7–15.3).
At univariate analysis, the factors that proved to have 
an impact upon survival were: factor T of gastric primary, 
the extent of hepatic involvement (factor H), the timing of 
hepatic metastases (synchronous vs metachronous), the cura-
tive effect of surgery, the recurrence of the disease, and the 
administration of chemotherapy. At multivariate analysis, all 
these factors except the timing of hepatic metastases were 
confirmed (Table 3). In detail, T4 gastric cancer, H3 hepatic 
involvement, non-curative resection, recurrence after sur-
gery, and the abstention from chemotherapy were associated 
with a worse prognosis. Factors T and H are the sole clini-
cal factors that may be considered in a preoperative phase 
in the selection of patients to be submitted to surgery; they 
displayed a clear (p < 0.001) cumulative effect.
Discussion
Our analysis shows that the extension of gastric primary 
(factor T) and the extension of hepatic disease (factor 
H) are the only clinical factors that influence survival 
in the subgroup of gastric cancer patients with hepatic 
metastasis. These factors were already found to have a 
prognostic role in this subgroup of patients [3, 9, 11, 20]; 
we confirm that there are very few clinical factors that can 
drive the selection of the best candidates for surgery in the 
metastatic setting of gastric cancer. The other prognos-
tic factors that emerge from our analysis are the curative 
















Type of hepatic resection
 Metastasectomy 108 75.0
 Segmentectomy 24 16.7
 Major resection 12 8.3







 Pre- and postoperative 4 2.8
Type of preoperative chemotherapy (synchronous)
 Fluorouracil 0 0.0
 Fluorouracil + platinum 2 12.5
 Fluorouracil + taxanes 1 6.2
 Other 13 81.3
Type of postoperative chemotherapy (synchronous)
 Fluorouracil 3 10.7
 Fluorouracil + platinum 5 17.8
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effect of surgery, recurrence of disease, and administration 
of chemotherapy.
In a recent meta-analysis from Markar et al. [23] that ana-
lysed 39 studies on 991 patients treated with hepatic resec-
tion for gastric cancer metastases, the number of hepatic 
metastases and the type of liver involvement, the factor T 
and N of gastric primary, the vascular invasion, and the cura-
tive effect of surgery were reported as prognostic factors. 
The prognostic role of the factor T of the gastric primary, 
negative when rated T4, is widely recognized [3–8]. Indeed, 
the serosal involvement is a watershed between a neoplasm 
still theoretically limited into the gastric wall and one with 
diffusive potential to the peritoneal cavity. As regard the 
prognostic role of the hepatic tumour burden (factor H), a 
general consensus exists. Besides all biological considera-
tions, it is worth noting that in H3 patients the percentage of 
non-curative resection was higher than in the H1–H2 group 
(40 vs 17.3%, respectively). Factors T and H displayed a 
cumulative negative impact upon survival: it dropped actu-
ally from 30 months in the case of T1–T3 and H1–H2 dis-
ease to 7.3 months for T4 and H3 patients (p < 0.001).
Our data confirm that the complete surgical removal of 
tumor bulk (both gastric tumor and hepatic  metastasis) is a 
major prognostic factor and it suggests that no efforts must 
be spared to achieve it, also referring to non-surgical abla-
tive techniques [4, 24, 25]. Median survival is 17 months 
Fig. 1  Overall survival
Table 3  Prognostic factors: univariate and multivariate analysis (only variables significant at univariate analysis are shown)
Prognostic variables n Median survival 
(months)
95% CI Univariate p value Multivariate 
p value
Hazard ratio 95% CI
pT 0.001 0.025 3.8 1.4–10.8
 T1–T2 21 5.0 16.9–53.1
 T3 27 20.0 6.4–33.5
 T4 65 10.2 6.5–13.8
Timing of hepatic metastases 0.004 n.s.
 Synchronous 109 11.2 7.6–14.7
 Metachronous 32 31.0 22.6–39.3
Hepatic involvement < 0.001 0.021 2.8 1.3–6.1
 H1 98 17.0 9.6–24.3
 H2 28 14.4 2.8–25.9
 H3 15 7.3 3.9–10.7
Curative effect < 0.001 0.010 5.8 1.8–15.8
 R0 15 17.0 12.1–21.9
 R1 13 6.6 5.6–7.5
 R2 13 8.0 4.9–11.1
Chemotherapy 0.030 < 0.001 3.8 2.0–7.4
 Yes 55 24.0 16.1–31.9
 No 86 13.0 9.9–16.1
Recurrence < 0.001 0.002 10.3 2.3–46.5
 No 19 116.0 99.3–132.7
 Yes 61 11.2 6.9–15.4
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after curative surgery, but drops to 7 months in the case 
of R + resection, which is similar to the median survival 
of patients submitted to palliative surgery or to supportive 
treatments [19, 20]. Our data on the role of curative surgery 
confirms those reported by some European authors [12, 15, 
26], but are in contrast with those reported by Cheon et al. 
[24], who observed no significative differences in survival 
performances after R0 or R + resections. This can be prob-
ably explained by the positive impact of chemotherapy that 
was administered to a higher percentage of patients (88 vs 
33.3%) in the Korean series. Moreover, we should consider 
the role of the different biologies of gastric cancer in Eastern 
and Western countries. Due to the retrospective nature of 
our study, it was difficult to analyse factors related to tumour 
biology, but we are well aware that further study is needed to 
examine this point [23, 27]. It is important to highlight that 
the surgical treatment of these patients should be referred to 
tertiary centres as the ones involved in our study, where post-
operative morbidity and mortality rate can be minimized.
The beneficial role of chemotherapy upon survival can be 
explained by the fact that hepatic metastases are expression 
of haematogenous diffusion; therefore, they can take advan-
tage of systemic treatment before or after surgical debulking. 
It is well known that a multidisciplinary approach is needed 
for the treatment of metastatic patients [15, 24, 28], but the 
timing of chemotherapy is still a matter of discussion, both 
for the treatment of non-metastatic and metastatic patients.
Chemotherapy displayed in this study a clear survival 
benefit (24.0 vs 13 months) and all the long-term survival 
patients had received chemotherapy. In Fig. 2 we show 
the huge impact of chemotherapy upon survival, dividing 
the study population into two groups: those who received 
chemotherapy and those who did not. Chemotherapy ame-
liorates survival also for patients with negative prognostic 
factors as T4 and H3 tumors, pushing the survival curve at 
the level of patients without risk factors who did not receive 
chemotherapy. At contrary, there are no survival chances 
for patients presenting risk factors if they do not receive 
systemic treatment.
Due to lack of data, we could not analyse the role of 
response to chemotherapy but we would like to prompt the 
collection of these data for further studies.
As could be expected, recurrence after surgery impacts 
unfavourably upon survival. Interestingly, 55.7% of patients 
who developed recurrence had not received chemotherapy 
and the absence of chemotherapy proved to be a risk factor 
for the development of disease recurrence (HR 2.9 CI 95% 
2.7–4.9; p < 0.001).
Our data do not allow an insight into the respective role 
of neoadjuvant and adjuvant chemotherapy in this subset of 
patients. This point will be focused on soon.
Conclusion
We can state that the surgical treatment of hepatic metasta-
sis from gastric cancer should be taken into consideration 
after careful evaluation of each single case, as only a radical 
approach with curative intent is worthy. Moreover a multi-
disciplinary treatment is necessary, as chemotherapy plays 
a fundamental role in the metastatic setting of the disease.
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